Respicardia Competitors, Revenue and Alternatives
Estimated Revenue & Financials
- Respicardia's estimated annual revenue is currently $14.8M per year.
- Respicardia received $58.5M in venture funding in December 2017.
- Respicardia's estimated revenue per employee is $242,770
- Respicardia's total funding is $98.4M.
- Respicardia has 61 Employees.
- Respicardia grew their employee count by 42% last year.
- Respicardia currently has 1 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|C-Axis and C-Ax...||$15.1M||71||1%||N/A|
What Is Respicardia?
Founded in 2006 and headquartered near Minneapolis, Minnesota, Respicardia® is dedicated to improving the lives of heart failure patients by developing implantable therapies designed to improve respiratory rhythm management and cardiovascular health. The first product, the remed® System, is an implantable stimulation device that is designed to restore a more normal breathing pattern during sleep for patients with central sleep apnea. Respicardia® is committed to improving cardiovascular healthone breath at a time.keywords:Biotechnology,Healthcare,Medical Devices,Pharmaceuticals
Number of Employees
Employee Growth %
|Tim Hauch||Chief Financial Officer||Email Available|
|Todd Goblish||VP Research/Development||Email Available|
|Michael Brown||South West Territory Manager||Email Available|
|Bill Reidy||Territory Manager||Email Available|
|Jodie Alwin||Director Of Medical Education And Training||Email Available|
|Mark Sartory||Territory Manager||Email Available|
|Blair Easton||Territory Manager||Email Available|
|Frank Piskolich||General Counsel||Email Available|
|Scott McKane||Senior Principal Statistician And Data Management||Email Available|
|Jill Fricke||Clinical Territory Manager||Email Available|
A new study of Respicardia's Remede central sleep apnea (CSA) implant showed long-term safety and sustained improvement in sleep metrics ...
“We're honored to continue supporting Respicardia in bringing their therapy to market,” said Tony Gonzalez, president of Integer's Cardiac ...
At Versant, he invested in a number of Minnesota companies like Metavention, Respicardia and Monteris Medical. Vensana, however, isn't ...
|2017-12-19||$58.5M||Undisclosed||ZOLL Medical Corporation||Article|
Respicardia Executive Hires
|2012-11-28||Jay Millerhagen||VP Clinical Affairs/Market Development||Article|